TABLE 2.
Treatment persistence and adherence during 12-month follow-up.
| Variable | Total | Single-inhaler triple therapy (SITT) | Multiple-inhaler triple therapy (MITT) | p-value |
|---|---|---|---|---|
| N = 1328 | N = 535 | N = 793 | ||
| Persistence, n (%) | ||||
| 6 months | 1096 (82.5) | 463 (86.5) | 633 (79.8) | 0.006 |
| 12 months | 845 (63.6) | 388 (72.5) | 457 (57.6) | < 0.001 |
| Treatment persistence days, mean (SD) | 287.1 (105.5) | 304.6 (97.5) | 275.3 (109.5) | < 0.001 |
| PDC>0.8, n (%) | ||||
| 6 months | 1098 (82.7) | 463 (86.5) | 635 (80.1) | 0.008 |
| 12 months | 927 (69.8) | 411 (76.8) | 516 (65.1) | < 0.001 |
| Persistence | Cox proportional hazards model** | |||
| HR (95% CI) | 1.676 (1.356-2.071) | < 0.001 | ||
Abbreviations: PDC, proportion of days covered.